Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant reduction in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5].

Core Points - InterGlobe Aviation, operator of IndiGo, will be included in the BSE Sensex index starting December 22 [3][4] - Tata Motors Passenger Vehicles Ltd will be removed from the BSE Sensex index as part of the reconstitution [3][4] - IDFC First Bank Ltd will be added to the BSE 100 index, replacing Adani Green Energy Ltd [3][4] - Max Healthcare Institute Ltd will be included in the BSE Sensex 50 index, while IndusInd Bank Ltd will be removed [3][4] - In the BSE Sensex Next 50 index, IndusInd Bank and IDFC First Bank will replace Max Healthcare Institute and Adani Green Energy [3][4]

Core Viewpoint - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][3]. Financial Performance - On November 12, 2025, Ardent reported a $43 million decrease in revenue for Q3 2025 after conducting evaluations of historical collection trends [4]. - The company also increased its professional liability reserves by $54 million due to adverse claim developments from 2019 to 2022 and broader industry trends [4]. - Following these disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [4]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages affected investors to seek additional information and potential legal options [2][5]. - The law firm operates on a contingency fee basis, meaning shareholders are not responsible for court costs or litigation expenses [5]. Company Overview - Ardent Health, Inc. provides healthcare services in mid-sized urban communities across the U.S., operating a network of hospitals, ambulatory facilities, and physician practices [3].

Financial Data and Key Metrics Changes - The company reported a 5% decline in total adjusted EBITDA, primarily due to weaker performance in Mexico [6][9] - Adjusted net income for the quarter was PEN 58 million, with a 1% increase in FX-neutral consolidated revenue driven by Peru and Colombia [9][18] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's top line and EBITDA grew by 9% and 15% respectively, driven by an improving healthcare pricing mix and strong insurance MLR [7][18] - Colombia's revenue increased by 5%, supported by risk-sharing models, with adjusted EBITDA rising by 18% [19][18] - Mexico experienced a 12% decline in revenue, although surgery volumes and oncology services showed growth [11][12] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, with a solid growth trajectory [21] - Colombia's revenue share from Nueva EPS decreased from 20% to 13%, indicating successful diversification of payers [19][45] - Mexico's revenue decline was attributed to a slow recovery in volumes and non-operating impacts from system migrations [21][9] Company Strategy and Development Direction - The company aims to enhance its growth in Mexico through a partnership with Sojitz, focusing on co-investment opportunities [32][39] - Auna is committed to maintaining a leverage ratio below three times net debt to EBITDA while pursuing growth initiatives [28][32] - The Trecca project in Peru is expected to generate significant revenue, with a focus on expanding services to state beneficiaries [53][56] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for a recovery in Mexico in 2026, despite current challenges [8][32] - The company remains focused on improving operational efficiency and expanding its market presence in Peru and Colombia [30][31] - Management highlighted the importance of attracting and retaining healthcare talent in Mexico to drive growth [13][15] Other Important Information - The company successfully refinanced $765 million in debt, improving its debt profile and financial flexibility [27][28] - Auna's cash position at the end of the quarter was PEN 226 million, reflecting a 4.2% decrease from the beginning of the year [26] Q&A Session Summary Question: Could you explain the rationale for expanding in Mexico and how it aligns with your deleveraging goals? - Management emphasized that the partnership with Sojitz will help accelerate growth in Mexico while maintaining leverage targets [39][40] Question: Do you think a change in Colombia's leadership could ease pressures on EPSs? - Management indicated that while political changes may not yield immediate results, there are signs of stabilization in the Colombian healthcare sector [40][41] Question: What key KPIs should be tracked to confirm a recovery in 2026? - Management suggested monitoring occupancy, payer mix, and surgical productivity as indicators of recovery [61] Question: What is the nature of the $500 million investment plan in Mexico? - Management confirmed that the investment plan is related to the MOU with Sojitz and aims to drive significant top-line growth [72] Question: How is Auna managing insurance risk at a group level? - Management explained that risk is managed through continuous repricing and cost containment strategies [75][78] Question: Have the preferred payer network and bundled packages for corporates been launched? - Management confirmed that the preferred payer network has been launched and is continuously evolving [79][80]

Auna (NYSE:AUNA) Q3 2025 Earnings Call November 21, 2025 08:00 AM ET Company ParticipantsNone - OperatorGisele Remy - CFO and EVPMauricio Cepeda - Equity Research Executive DirectorSuso Zamora - Executive Chairman and PresidentAna Maria Mora - Head of Investor RelationsNoneGood morning and welcome to Auna's Third Quarter 2025 Earnings Conference Call. My name is Eric, and I will be the operator for today's call. At this time, all participants are in listen-only mode, and please note that this call is being ...

Financial Data and Key Metrics Changes - The company reported weaker financial results for Q3 2025, with a 5% decline in total adjusted EBITDA primarily due to performance in Mexico [6][9] - Adjusted net income was PEN 58 million for the quarter, with FX-neutral consolidated revenue increasing by 1% [9][22] - Capacity utilization decreased by 3 percentage points to 64%, with a 1.5 percentage point increase in Peru offset by declines in Colombia and Mexico [9][10] Business Line Data and Key Metrics Changes - Peru's revenue grew by 9% and adjusted EBITDA increased by 15%, driven by improved healthcare pricing mix and strong insurance MLR [9][19] - Colombia's revenue grew by 5%, with adjusted EBITDA increasing by 18%, attributed to risk-sharing models and higher average tickets for surgery [20][21] - Mexico experienced a 12% revenue decline, although surgery volumes and oncology services increased [11][12] Market Data and Key Metrics Changes - Peru accounted for over half of the company's revenues, continuing to be a strong growth driver [21] - Colombia's share of revenues from major government payers decreased from 20% to 13%, indicating successful diversification efforts [20][21] - Mexico's revenue decline was influenced by a slower market and operational challenges, including the implementation of new IT systems [12][21] Company Strategy and Development Direction - The company is focused on capturing long-term growth opportunities in Mexico, anticipating a full recovery in 2026 [8][30] - Auna is rolling out new service offerings and enhancing collaboration with physicians to penetrate profitable market segments [14][15] - The partnership with Sojitz Corporation aims to accelerate growth in Mexico while maintaining a disciplined deleveraging path [31][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Mexico's recovery, highlighting stable hospital operations and increased service volumes [6][8] - The company remains committed to improving its leverage ratio to below three times net debt to EBITDA in the medium term [26][27] - Management acknowledged the challenges in Colombia but emphasized the strength of Auna's positioning and growth potential [36][38] Other Important Information - Auna successfully refinanced $765 million in debt, improving its debt profile and extending maturities [26][27] - The company is implementing a comprehensive IT system to enhance operational efficiency and data management [18] Q&A Session Summary Question: Future strategy in Mexico and the rationale for expanding - Management clarified that the partnership with Sojitz is aimed at accelerating growth in Mexico while maintaining leverage targets [34][35] Question: Potential changes in Colombia's leadership and their impact - Management indicated that while political changes may not yield immediate improvements, there are signs of stabilization in the Colombian healthcare sector [36][38] Question: Key KPIs to track for recovery in 2026 - Management highlighted occupancy, payer mix, and surgical productivity as critical KPIs to monitor for tangible recovery [44] Question: Recent share price weakness and institutional investor activity - Management noted that the current share price does not reflect the company's fundamentals and is evaluating options to enhance shareholder value [45] Question: Return on investment timeline for Mexico performance - Management expects 2026 to be a growth year for Mexico, despite setbacks in 2025 [47] Question: Expansion plans in Peru and Mexico - Management confirmed plans to increase capacity in both countries, focusing on high-complexity services [48] Question: Details on the partnership with Sojitz and investment plans - Management confirmed that the $500 million investment plan is related to the MoU with Sojitz, aimed at significant top-line growth [49][50]

Q3 2025 This presentation has been prepared by Auna S.A. ("Auna" or the "Company") solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other party without the Company's prior written consent is prohibited. This presentation contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These s ...

Core Insights - Ardent Health, Inc. is under investigation for potential violations of federal securities laws due to improper accounting practices related to accounts receivable and professional liability reserves [1][2]. Financial Performance - In Q3 2025, Ardent reported a $43 million decrease in revenue after conducting evaluations of historical collection trends [3]. - The company also increased its professional liability reserves by $54 million due to adverse developments from claims made between 2019 and 2022, as well as broader industry trends [3]. - Following the financial disclosures, Ardent's stock price dropped over 33% during trading on November 13, 2025 [3]. Legal Context - Bleichmar Fonti & Auld LLP is leading the investigation and encourages affected investors to seek additional information regarding potential legal options [1][4]. - The law firm operates on a contingency fee basis, meaning shareholders are not responsible for court costs or litigation expenses [4]. Company Overview - Ardent Health operates a network of hospitals, ambulatory facilities, and physician practices primarily in mid-sized urban communities across the U.S. [2].

Company Overview - HCA Healthcare is the largest for-profit operator of acute care hospitals in the U.S. with 191 hospitals and a network of 2,400 sites of care across 20 states and the U.K. [1] - In 2024, HCA Healthcare oversaw 44 million patient encounters, highlighting its significant presence in the healthcare sector [1]. Conference Details - The presentation took place during the Stephens 2025 Annual Investment Conference in Nashville, with Raj Kumar serving as the health care services analyst [1]. - Mike Marks, Executive Vice President and CFO of HCA Healthcare, was present to discuss the company's performance and future outlook [1].

Core Insights - Auna reported solid financial and operational performance in Peru and Colombia, while facing challenges in Mexico, indicating resilience in its integrated healthcare platform [3][4][6] Financial Performance - Consolidated Revenue increased by 1% in constant currency (FXN) but decreased by 1% year-over-year (YoY) to S/1,117 million, with local currency revenues growing by 9% in Peru and 4% in Colombia, offset by a 12% decline in Mexico [8][10] - Adjusted EBITDA decreased by 5% FXN and 7% YoY to S/232 million, with a margin of 20.8%, down from 22.1% YoY; Peru and Colombia saw increases of 15% and 18% in local currency, respectively, while Mexico experienced a 29% decline [8][11] - Net Income was S/53 million in 3Q25, down from S/101 million in 3Q24, with Adjusted Net Income at S/58 million compared to S/75 million in the prior year [13] Operational Highlights - In Peru, Oncosalud and Healthcare Services showed strong performance due to growth in memberships and pricing adjustments, with an improved Oncology Medical Loss Ratio (MLR) of 49.3% [4][8] - Colombia achieved double-digit growth in Adjusted EBITDA and expanded risk-sharing Prospective Global Payment models, enhancing profitability and cash generation [5][8] - Mexico's operations saw a second consecutive quarterly increase in surgeries and growth in oncology and cardiology services, but overall revenues and profitability declined due to sluggish demand and operational challenges [6][10] Debt and Capital Structure - Auna's leverage ratio remained stable at 3.6x Net Debt-to-Adjusted EBITDA, with a focus on capital allocation and a robust cash position; the company completed a USD765 million debt refinancing to extend maturities and reduce interest costs [7][8] Strategic Initiatives - The company is focused on recovering growth, rolling out the AunaWay initiative in Mexico, and expanding access to high-quality healthcare across Spanish-speaking Latin America [9][10]